Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
379 studies found for:    Endometrial Cancer: Clinical Trials
Show Display Options
RSS Create an RSS feed from your search for:
Endometrial Cancer: Clinical Trials
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery
Condition: Endometrial Cancer
Intervention: Radiation: radiation therapy
2 Suspended Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06
Conditions: Endometrial Cancer;   Gastrointestinal Complications;   Radiation Toxicity;   Urinary Complications
Intervention: Radiation: 45 Gy/25 fractions
3 Unknown  A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial Cancer
Condition: Prosthesis Survival
Interventions: Radiation: radiotherapy;   Drug: Cisplatin;   Drug: Cisplatin and Doxorubicin and Cyclophosphamide;   Drug: Paclitaxel and Carboplatin
4 Recruiting Trial Between Two Follow up Regimens With Different Test Intensity in Endometrial Cancer Treated Patients
Condition: Endometrial Cancer
Interventions: Procedure: Intensive/Low-Risk Treatment (IA G1; IA G2);   Procedure: Intensive/High-Risk Treatment (≥ IA G3);   Procedure: Minimalist/Low-Risk Treatment (IA G1; IA G2);   Procedure: Minimalist/High-Risk Treatment (≥ IA G3)
5 Active, not recruiting Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Radiation: Radiation Therapy;   Drug: cisplatin;   Drug: carboplatin;   Drug: Paclitaxel
6 Completed Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)
Condition: Endometrial Cancer
Interventions: Drug: ridaforolimus;   Drug: medroxyprogesterone acetate tablets OR megestrol acetate;   Drug: chemotherapy
7 Not yet recruiting Trial of Letrozole +/- Palbociclib in Metastatic Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Drug: Palbociclib;   Drug: Letrozole
8 Active, not recruiting Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer
Conditions: Ovarian Cancer;   Endometrial Cancer;   Fallopian Cancer;   Peritoneal Cancer
Interventions: Biological: E39 peptide vaccine;   Other: Clinical tracking for disease progression/recurrence
9 Completed Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer
Condition: Endometrial Carcinoma
Intervention: Drug: carboplatin, paclitaxel, and bevacizumab
10 Recruiting Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
Conditions: Ovarian Cancer;   Endometrial Cancer
Intervention: Drug: everolimus and letrozole
11 Completed 2D Versus 3D Radical Laparoscopic Hysterectomy for Endometrial Cancer: a Prospective Randomized Trial
Condition: Endometrial Cancer
Interventions: Procedure: 3D Laparoscopy;   Procedure: Standard Laparoscopy
12 Not yet recruiting Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients
Condition: Recurrent Endometrial Cancer
Interventions: Drug: Olaparib;   Drug: metformin;   Drug: metronomic cyclophosphamide
13 Not yet recruiting Selective Targeting of Adjuvant Therapy for Endometrial Cancer (STATEC)
Condition: Endometrial Cancer
Interventions: Procedure: Abdominal surgery;   Procedure: Lymphadenectomy
14 Completed Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer
Condition: Endometrial Cancer
Intervention: Drug: letrozole
15 Completed Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Drug: ridaforolimus;   Genetic: gene expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
16 Completed
Has Results
Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma;   Stage IIIA Endometrial Carcinoma;   Stage IIIB Endometrial Carcinoma;   Stage IIIC Endometrial Carcinoma;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma
Interventions: Drug: temsirolimus;   Other: laboratory biomarker analysis
17 Completed Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Procedure: adjuvant therapy;   Procedure: conventional surgery;   Radiation: brachytherapy;   Radiation: radiation therapy
18 Terminated Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Conditions: Uterine Cervical Cancer;   Endometrial Cancer
Intervention: Drug: Zalypsis ( PM00104)
19 Completed Diet and Physical Activity in Uterine Cancer Survivors
Condition: Endometrial Neoplasms
Intervention: Behavioral: Shape-Up following cancer treatment
20 Recruiting Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer
Condition: Stage III-IV or Recurrent Endometrial Cancer
Interventions: Drug: Bevacizumab;   Drug: Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.